“This institutional placement of A$50m at this time strengthens Opthea’s cash position as we explore a number of strategic development opportunities, and enables the Company to fund its operations into the first half of calendar year 2021. The completion of this placement will allow Opthea to expeditiously progress our Phase 3 clinical development program with OPT-302.”
The quote above from Megan Baldwin was part of a Motley Fool update on Opthea following the recent CR announcement. Reading between the lines the bit about "as we explore a number of strategic development options" I would interpret as potential partnerships/licensing agreements but I suspect they will hold fire until the DME trial results are out which if successful will further enhance the value of the company. In the meantime I imagine the volatility in share price will continue for the next few months
“This institutional placement of A$50m at this time strengthens...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
0.005(1.47%) |
Mkt cap ! $376.5M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 35.0¢ | 33.5¢ | $986.8K | 2.875M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 55705 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 29727 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |